CN1256120C - Medicine for treating chronic pelvic inflammation and its preparing method - Google Patents
Medicine for treating chronic pelvic inflammation and its preparing method Download PDFInfo
- Publication number
- CN1256120C CN1256120C CN 200410010750 CN200410010750A CN1256120C CN 1256120 C CN1256120 C CN 1256120C CN 200410010750 CN200410010750 CN 200410010750 CN 200410010750 A CN200410010750 A CN 200410010750A CN 1256120 C CN1256120 C CN 1256120C
- Authority
- CN
- China
- Prior art keywords
- portions
- hours
- parts
- volatile oil
- decocted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 title claims abstract description 16
- 230000001684 chronic effect Effects 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title claims description 42
- 238000000034 method Methods 0.000 title abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000007788 liquid Substances 0.000 claims abstract description 39
- 239000000341 volatile oil Substances 0.000 claims abstract description 28
- 241000218176 Corydalis Species 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000706 filtrate Substances 0.000 claims abstract description 18
- 239000000796 flavoring agent Substances 0.000 claims abstract description 15
- 235000019634 flavors Nutrition 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 230000035619 diuresis Effects 0.000 abstract description 4
- 230000036407 pain Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000003405 preventing effect Effects 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000972672 Phellodendron Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 1
- 240000009022 Smilax rotundifolia Species 0.000 abstract 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 description 38
- 230000004054 inflammatory process Effects 0.000 description 38
- 241000700159 Rattus Species 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000002683 foot Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 235000009161 Espostoa lanata Nutrition 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- RTBLDXVIGWSICW-JMSVASOKSA-N (1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-ene Chemical compound C[C@@H]1CC[C@@H]2CC3=C(C)CC[C@]13C2(C)C RTBLDXVIGWSICW-JMSVASOKSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- -1 carboxyl tanshinone Chemical compound 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- YOVSPTNQHMDJAG-QLFBSQMISA-N β-eudesmene Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C YOVSPTNQHMDJAG-QLFBSQMISA-N 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 3
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930014456 matrine Natural products 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- UXYJCYXWJGAKQY-HNNXBMFYSA-N (S)-stylopine Chemical compound C1C2=C3OCOC3=CC=C2C[C@@H]2N1CCC1=C2C=C(OCO2)C2=C1 UXYJCYXWJGAKQY-HNNXBMFYSA-N 0.000 description 2
- KDFKJOFJHSVROC-INIZCTEOSA-N (S)-tetrahydrocolumbamine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(O)=C2 KDFKJOFJHSVROC-INIZCTEOSA-N 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- JEDBBFHVVHKMKS-UHFFFAOYSA-N 5,7-dimethoxy-8-(3-methylbut-2-enoyl)chromen-2-one Chemical compound C1=CC(=O)OC2=C(C(=O)C=C(C)C)C(OC)=CC(OC)=C21 JEDBBFHVVHKMKS-UHFFFAOYSA-N 0.000 description 2
- XDUXBBDRILEIEZ-UHFFFAOYSA-N 6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 2
- QRMPRVXWPCLVNI-YYFQZIEXSA-N Curcumol Chemical compound C1C(=C)[C@@H]2CC[C@H](C)[C@@]22C[C@@H](C(C)C)[C@]1(O)O2 QRMPRVXWPCLVNI-YYFQZIEXSA-N 0.000 description 2
- AJFJTORMMHWKFW-UHFFFAOYSA-N Dhelwangin Chemical compound CC(C)CCC(=O)C1=C(O)C=C(C)OC1=O AJFJTORMMHWKFW-UHFFFAOYSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 2
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 2
- VQYBAEAOOJBSTR-QHSBEEBCSA-N Sophoranol Chemical compound C([C@@H]12)CCC(=O)N1C[C@@]1(O)[C@H]3[C@@H]2CCCN3CCC1 VQYBAEAOOJBSTR-QHSBEEBCSA-N 0.000 description 2
- VQYBAEAOOJBSTR-AYRXBEOTSA-N Sophoranol Natural products O=C1N2[C@H]([C@@H]3[C@@H]4[C@](O)(C2)CCCN4CCC3)CCC1 VQYBAEAOOJBSTR-AYRXBEOTSA-N 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 2
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 2
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 2
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- YOVSPTNQHMDJAG-UHFFFAOYSA-N beta-helmiscapene Natural products C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- KUFXJZXMWHNCEH-UHFFFAOYSA-N cyperone Natural products C1CC(=O)C(C)=C2CC(C(=C)C)CCC21C KUFXJZXMWHNCEH-UHFFFAOYSA-N 0.000 description 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- IEICDHBPEPUHOB-UHFFFAOYSA-N ent-beta-selinene Natural products C1CCC(=C)C2CC(C(C)C)CCC21C IEICDHBPEPUHOB-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- FQEQMASDZFXSJI-RWMBFGLXSA-N (-)-Anagyrine Natural products C([C@@H]12)CCCN1C[C@H]1C3=CC=CC(=O)N3C[C@@H]2C1 FQEQMASDZFXSJI-RWMBFGLXSA-N 0.000 description 1
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 1
- CULUKMPMGVXCEI-NXEZZACHSA-N (-)-N-Methylcytisine Natural products C12=CC=CC(=O)N2C[C@H]2CN(C)C[C@H]1C2 CULUKMPMGVXCEI-NXEZZACHSA-N 0.000 description 1
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- FQEQMASDZFXSJI-UHFFFAOYSA-N Anagyrin Natural products C12CCCCN2CC2C3=CC=CC(=O)N3CC1C2 FQEQMASDZFXSJI-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 1
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- APWLDLGOYJHNIK-YUELXQCFSA-N Cyperol Chemical compound C1C[C@@H](O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C APWLDLGOYJHNIK-YUELXQCFSA-N 0.000 description 1
- APWLDLGOYJHNIK-CFVMTHIKSA-N Cyperol Natural products O[C@H]1C(C)=C2[C@](C)(CC1)CC[C@H](C(=C)C)C2 APWLDLGOYJHNIK-CFVMTHIKSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- CULUKMPMGVXCEI-UHFFFAOYSA-N N-methylcystisine Natural products C12=CC=CC(=O)N2CC2CN(C)CC1C2 CULUKMPMGVXCEI-UHFFFAOYSA-N 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- IPVSUYLZIAYTOK-VWVAXHKFSA-O Peonin Natural products O(C)c1c(O)ccc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)cc(O)cc3[o+]2)c1 IPVSUYLZIAYTOK-VWVAXHKFSA-O 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 1
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- FQEQMASDZFXSJI-YNEHKIRRSA-N anagyrine Chemical compound C([C@@H]12)CCCN1C[C@H]1C3=CC=CC(=O)N3C[C@H]2C1 FQEQMASDZFXSJI-YNEHKIRRSA-N 0.000 description 1
- ICFWMXKHGNCJTK-UHFFFAOYSA-N anagyrine Natural products O=C1C=CC=C2C3CC(CC4CCCCN4C3)N12 ICFWMXKHGNCJTK-UHFFFAOYSA-N 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- FDABVSXGAMFQQH-XZWHSSHBSA-N berbamunine Chemical compound CN1CCC2=CC(OC)=C(O)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@@H]2N(C)CCC=3C=C(C(=CC=32)O)OC)=C1 FDABVSXGAMFQQH-XZWHSSHBSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 235000004654 carnosol Nutrition 0.000 description 1
- CULUKMPMGVXCEI-UWVGGRQHSA-N caulophylline Chemical compound C12=CC=CC(=O)N2C[C@@H]2CN(C)C[C@@H]1C2 CULUKMPMGVXCEI-UWVGGRQHSA-N 0.000 description 1
- 229930193256 caulophylline Natural products 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 229930017327 cytisine Natural products 0.000 description 1
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 1
- 229940027564 cytisine Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000009835 oxypaeoniflora Substances 0.000 description 1
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 1
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- KDFKJOFJHSVROC-UHFFFAOYSA-N tetrahydrocolumbamine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(O)=C2 KDFKJOFJHSVROC-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine for treating chronic pelvic inflammation and a preparing method thereof, which belong to the field of traditional Chinese medicine. The present invention is prepared from raw medicinal materials of 170 to 210 portions of angelica, 170 to 210 portions of red sage root, 95 to 135 portions of red peony root, 95 to 135 portions of corydalis tuber, 95 to 135 portions of prism tuber, 95 to 135 portions of zedoary, 95 to 135 portions of flavescent sophora root, 95 to 135 portions of phellodendron, 95 to 135 portions of glabrous greenbrier rhizome and 55 to 95 portions of nutgrass galingale rhizome by weight. The raw medicinal materials are put in an extracting tank with a volatile oil extractor, and are decocted for three times by adding water. The extracted volatile oil is preserved in another device, and the decoction liquid is merged and filtered. Filtrate is concentrated until the relative density is from 1.10 to 1.15 at 20DEG C, and is stood for 24 hours by adding ethanol, and ethanol is recovered until no ethanol flavor exists. The extracted volatile oil is dissolved by a little ethanol, and is sprayed in powder. The medicine of the present invention has conspicuous efficiency of promoting blood circulation for removing blood stasis, clearing away heat, promoting diuresis, eliminating mass and alleviating pain. The present invention has good preventing and curative effects for pelvic inflammatory disease and annexitis.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Chronic pelvic inflammatory disease is a common gynecological disease, one of frequently-occurring disease, in recent years, the summary of situations such as utilization theory of Chinese medical science or modern relevant this kind research is the main Radix Salviae Miltiorrhizae that adopts in Therapeutic Method and the utilization of square medicine, Rhizoma Corydalis, Radix Angelicae Sinensis, Radix Paeoniae Rubra, rhizoma sparganic, medicines such as Rhizoma Cyperi, regulating QI to promote menstruation, blood circulation promoting and blood stasis dispelling, make it to quicken blood flow, improve blood circulation, make blood can supply with the nutrition of organ and tissue, keep muscle, neural NE, the function that enhance immunity and body fluid are regulated, promote the reparation and the regeneration of inflammation tissue, thereby suppress the production breeding of multiple pathogenic bacteria, Intrapelvic inflammation is absorbed and elimination, Caulis Sargentodoxae in addition again, Herba Patriniae, Cortex Phellodendri, heat-clearing and toxic substances removing such as Radix Sophorae Flavescentis, the effect of blood-activating analgetic, multiple pathogenic bacteria is killed and inhibitory action, and certain antivirus action is arranged, collaborative activating blood and removing stasis drug, further reach the elimination pelvic inflammation, recover the purpose of genitals's physiological function.
In a word, at the feature of chronic pelvic inflammatory disease, at present with drug for invigorating blood circulation and eliminating stasis, it is main that wet medicine is separated in heat clearing away, and does not also have based on the Chinese medicine of eliminating mass pain relieving.
Summary of the invention
The invention provides a kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof, to solve present treatment chronic pelvic inflammatory disease not based on the problem of the Chinese medicine of eliminating mass pain relieving.
The present invention selects the medicine prescription on the basis of clinical experience, separate wet medicine based on drug for invigorating blood circulation and eliminating stasis, heat clearing away, secondly is the eliminating mass analgesic.Meet theory of Chinese medical science, this is because pelvic inflammatory disease belongs to sick categories such as the traditional Chinese medical science " dysmenorrhea ", " leukorrhagia ", " lump in the abdomen ".Its pathology origin cause of formation is for passing through, puerperal the vessels of the uterus inanition, bathing is unclean, invades in the damp and hot heresy, or among the not empty stasis of blood knot of the surplus heresy born of the same parents, is subjected to evil poison again, pents up to form.So the suitable blood circulation promoting and blood stasis dispelling of the rule of treatment, clearing away heat-damp and promoting diuresis, eliminating mass pain relieving.
Analyze above process, we be method with activating blood and eliminatng dampness as the prescription foundation, use for many years clinically, have tangible blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis, eliminating mass analgesic effect, for pelvic inflammatory disease, adnexitis has prevention and therapeutical effect preferably.
Monarch drug in the side of being classified as, sweet, hot, warm, mainly contain volatile oil, composition is ligustilide (ligustilide accounts for 47%), angelicone, positive fourth alkene Fu lactone etc. in the oil.In addition, still contain ferulic acid (ferulic acid), nicotinic acid, succinic acid, several amino acids and Radix Angelicae Sinensis polysaccharide.This product adopts thin layer chromatography that it has been carried out qualitative identification.
Radix Salviae Miltiorrhizae is the ministerial drug in this product, mainly contains anthraquinone analog compounds such as Tanshinone I (tanshinone I), tanshinone (tanshinone IIA), Tanshinone II B (tanshinone IIB), Methyl tanshinoate, carboxyl tanshinone and dihydrotanshinone I and water soluble ingredient protocatechualdehyde, danshensu.In addition, still contain miltirone and carnosol etc.This product adopts thin layer chromatography that it is carried out qualitative identification.
Radix Paeoniae Rubra is the ministerial drug in this product, mainly contains peoniflorin (Preoniflorin), lactone glucoside of Radix Paeoniae, oxypaeoniflorin, benzoylpaeoniflorin, peonin, lacdtlorin, Radix Paeoniae Rubra first element, second element, benzoic acid, tannin, volatilization wet goods.This product adopts thin layer chromatography that it is differentiated.
Rhizoma Corydalis is the ministerial drug in this product, mainly contain multiple alkaloid, include Rhizoma Corydalis first element (d-corydaline), tetrahydropalmatine (tetrahydropalmatine), Rhizoma Corydalis third element (protopine), Rhizoma Corydalis fourth element (l-tetrahydrocoptisine), Rhizoma Corydalis penta element (tetrahydrocolumbamine), hot plain (corydalis H) Rhizoma Corydalis element in the ninth of the ten Heavenly Stems of Rhizoma Corydalis, Rhizoma Corydalis element in the last of the ten Heavenly stems, Rhizoma Corydalis large rope element, corydalis, Rhizoma Corydalis element in the third of the twelve Earthly Branches etc.
Rhizoma sparganic is the ministerial drug in this product, mainly contains starch and volatile oil.
Rhizoma Curcumae is the ministerial drug in this product, mainly contains volatile oil 0.4-0.7%, and composition is α in the oil, nopinene, camphene, limonene, turmerone (turmerone), curcumenol (curcumol), linalool (linalool) etc.
Radix Sophorae Flavescentis is the adjuvant drug in this product, mainly contain multiple alkaloid, include matrine (matrine), oxymatrine (oxymatrine), sophor-anol (sophoranol), Radix Sophorae Flavescentis alkene alkali (sophocarpine), other matrine (sllomatrine), cytisine, caulophylline, anagyrine etc.This product adopts thin layer chromatography that it has been carried out qualitative identification.
Cortex Phellodendri is the adjuvant drug in this product, mainly contains the about 2-3% of berberine (berberine), and contains a small amount of phellodendrine (phellodendrine), palmatine, jateorhizine, magnoline, candicine, Caulis menispermi and appoint alkali etc.In addition, still contain obakulactone (obakulactone) and obacunone (obakunone).This product adopts thin layer chromatography that it has been carried out qualitative identification.
Rhizoma Smilacis Glabrae is the adjuvant drug in this product, mainly contains multiple steroidal saponin, and hydrolysis generates diosgenin (diosgenin), replaces and accuse sapogenin (tigognin).In addition, still contain alkaloid, volatilization wet goods composition.
Rhizoma Cyperi is the messenger drug in this product, and it is about 1% mainly to contain volatile oil, and composition is cyperone (cyperone), cyperol (cypero), cyperene (cyperene), β-selinene (β-selinene), Pogostone etc. in the oil.
The consumption of drug component of the present invention is groped to sum up in a large amount of clinical experiences through the inventor and is drawn, and each amounts of components is for all having better curative effect in following weight range:
Radix Angelicae Sinensis 170-210 part Radix Salviae Miltiorrhizae 170-210 part Radix Paeoniae Rubra 95-135 part Rhizoma Corydalis 95-135 part
Rhizoma sparganic 95-135 part Rhizoma Curcumae 95-135 part Radix Sophorae Flavescentis 95-135 part Cortex Phellodendri 95-135 part
Rhizoma Smilacis Glabrae 95-135 part Rhizoma Cyperi 55-95 part.
Be preferably:
115 parts of 115 parts of Rhizoma Corydalis of 190 parts of Radix Paeoniae Rubra of 190 parts of Radix Salviae Miltiorrhizaes of Radix Angelicae Sinensis
115 parts of 115 portions of Cortex Phellodendris of 115 parts of Radix Sophorae Flavescentiss of 115 parts of Rhizoma Curcumae of rhizoma sparganic
75 parts of 115 portions of Rhizoma Cyperis of Rhizoma Smilacis Glabrae.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations.Preferably, the preparation method of medicine activity component of the present invention is as follows:
A) take by weighing each crude drug, standby;
B) above-mentioned ten flavor crude drug are put in the extraction pot that has volatile oil extractor, decocted with water three times, add 14-9 for the first time and doubly measure, decocted 4 hours, and added 10-7 for the second time and doubly measure, decocted 3 hours, add 7-4 for the third time and doubly measure, decocted 3 hours, with carry volatile oil in addition device preserve, collecting decoction filters, and it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adding ethanol makes and contains alcohol amount and reach 50%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to there not being the alcohol flavor;
C) above-mentioned medicinal liquid is concentrated into the clear paste that relative density is 1.30-1.35, drying gets dry extract.
D) above-mentioned dry extract is broken into powder, with extract volatile oil with a little dissolve with ethanol, sparge in the powder, just be prepared into the active component of invention medicine.
The preparation method of medicine of the present invention is put above-mentioned ten flavor crude drug in the extraction pot that has volatile oil extractor in step b), decocts with water three times, for the first time add 10 times of amounts, decocted 4 hours, add 8 times of amounts for the second time, decocted 3 hours, and added 6 times of amounts for the third time, decocted 3 hours, with carry volatile oil in addition device preserve, collecting decoction filters, it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adds ethanol and makes and contain the alcohol amount and reach 50%, leaves standstill 24 hours, filter, filtrate recycling ethanol is to there not being the alcohol flavor.
The preparation method of medicine of the present invention, wherein the component that step b) is made-4 ℃ freezing 12 hours, treat under its room temperature slowly dissolving after, filter, filtrate adds 400 parts of refined honeys, 15 parts of steviosin, 2.5 parts of sodium benzoate; The volatile oil of carrying is added with medicinal dissolve with ethanol, and adding distil water is adjusted total amount to 1000ml, shakes up, filter, and fill, sterilization promptly gets oral liquid.
The active component of medicine of the present invention can add various conventional adjuvant required when preparing different dosage form, be prepared into any peroral dosage form commonly used as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine, as pill, powder, tablet, granule, capsule, oral liquid etc.
Medicine of the present invention has tangible blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis, eliminating mass analgesic effect, and for pelvic inflammatory disease, adnexitis has prevention and therapeutical effect preferably.
The specific embodiment
Below further set forth the beneficial effect of medicine of the present invention by testing example, these test pharmacodynamics test and acute toxicity test and long term toxicity test that examples have comprised medicine of the present invention (to call woman's inflammation oral liquid that disappears in the following text).
Experiment material
The test drug woman inflammation oral liquid that disappears is a brown liquid, and 2.5g (crude drug)/ml is made into distilled water before the experiment and contains crude drug 10g, 5g and 2.5g among every 10ml.Positive control drug is FUYANKANG (functional similarity cures mainly identical) 0.25 powder/grain, and lot number is 940429.
Reagent: carrageenin is available from pharmacological room of Shenyang Pharmacy College, the equal commercially available prod of other reagent.
Animal: the Wistar rat, body weight 140-170g, Kunming mouse body weight 18-22g, male and female half and half, available from provincial institute for drug control, quality certification lot number is 93000007,9302003.
Instrument: the LIANG-100 microcomputer shows record blood viscometer automatically, Shanghai Medical Univ Medical Instruments development center.
All through t check processing, the result is represented by X ± SD experimental data.
Experimental technique and result
One, the influence of xylol induced mice ear swelling
Get 50 of ♀ mices, divide 5 groups at random, irritate respectively stomach 10ml/kg distilled water, 1g (part)/kg, (4/kg) FUYANKANG tablet, 10,5.0 and the 2.5g/kg woman inflammation oral liquid that disappears, once a day, continuous 7 days, after the last administration 1 hour, drip respectively at mice left side ear and to be coated with 0.03ml/ dimethylbenzene, put to death mice after 2 hours, with the card punch of diameter 9mm, take off a left and right sides ear part and weigh, represent the swelling degree with the difference of left and right sides weight.The results are shown in Table 1.
The disappear influence of oral liquid xylol induced mice ear swelling of table 1 woman inflammation
| Group (g/kg) | Number of animals (only) | Swelling degree (mg) | P |
| Contrast FUYANKANG 1.0 woman's inflammation oral liquid 10.0 5.0 2.5 that disappears | 10 10 10 10 10 | 14.6±3.63 8.8±4.02 10.5±3.06 11.0±3.13 11.6±4.55 | ＜0.01 ＜0.05 ＜0.05 ＞0.05 |
The result shows: woman's inflammation oral liquid that disappears can significantly alleviate mice ear due to the dimethylbenzene.
Two, to the influence of rat paw edema due to the freshly-slaughtered poultry Ovum Gallus domesticus album
Get 50 of male rats, divide 5 groups at random, press the gastric infusion of dosage shown in the table 2, once a day, continuous 7 days.After the last administration 1 hour, the sole of the foot is subcutaneous in the rat right side, and 0.1ml/ in injection freshly-slaughtered poultry Ovum Gallus domesticus album is in injecting preceding 1 hour and injecting the back 0.5,1,2,3,4 and 5 hour, measure girth around right back ankle joint and the sufficient sole of the foot with narrow rule respectively, thus before and after scorching the two girth and difference as the foot swelling degree.The results are shown in Table 2.
The table 2 woman inflammation oral liquid that disappears causes the influence of rat paw edema to freshly-slaughtered poultry Ovum Gallus domesticus album
| Group (g/kg) | Number of animals (only) | Cause scorching back different time (hour) foot swelling degree (mm) | |||||
| 0.5 | 1 | 2 | 3 | 4 | 5 | ||
| Contrast FUYANKANG 1.0 woman's inflammation disappear 10.0 5.0 2.5 | 11 10 11 10 10 | 17.72±3.34 15.60±2.63 14.50±3.68 15.15±1.67 * 16.15±2.54 | 15.32±3.05 11.80±2.36 ** 10.91±2.55 ** 12.40±2.41 * 13.05±1.21 * | 13.09±2.26 9.80±2.52 ** 9.00±2.00 *** 8.65±1.92 *** 9.95±2.11 * | 11.23±2.02 8.30±2.72 ** 6.82±2.18 *** 6.82±2.18 *** 8.80±2.04 * | 10.0±2.24 6.80±3.00 ** 5.45±1.29 *** 6.35±0.94 *** 7.35±1.90 ** | 8.94±2.03 5.50±2.75 ** 4.54±1.63 *** 4.15±1.42 *** 5.60±1.47 ** |
Compare with matched group
*Expression P＜0.05
*Expression P＜0.01
* *P＜0.001
The result shows: woman's inflammation oral liquid that disappears can significantly suppress by the rat paw edema due to the freshly-slaughtered poultry Ovum Gallus domesticus album.
Three, the influence of the rat paw edema due to the on Carrageenan
The experiment grouping, administering mode and time are the same.After the last administration 1 hour, subcutaneous in the right sole of the foot of rat, only inject 0.8% carrageenin 0.1ml/, in preceding 1 hour of injection and injection the last 1,2,3,4,5 and 6 hour, measure right back foot swelling degree with narrow rule respectively, method is the same.The results are shown in Table 3.
The table 3 woman inflammation oral liquid on Carrageenan that disappears causes the influence of rat paw edema
| Group (g/kg) | Number of animals (only) | Cause scorching back different time (hour) foot swelling degree (mm) | |||||
| 1 | 2 | 3 | 4 | 5 | 6 | ||
| Contrast FUYANKANG 1.0 woman's inflammation disappear 10.0 5.0 2.5 | 10 10 10 10 10 | 4.60±1.91 3.45±1.64 3.71±1.00 3.75±2.12 3.95±1.97 | 11.70±2.12 8.30±2.34 ** 7.80±3.23 ** 8.85±2.38 * 8.70±3.89 | 13.70±1.38 10.55±2.25 ** 11.10±2.93 * 11.75±2.25 * 12.90±4.30 | 15.25±1.97 11.40±1.88 ** 11.80±3.36 * 12.05±2.25 ** 13.80±3.94 | 13.90±184 12.00±2.52 11.70±3.06 12.20±2.35 13.25±3.13 | 12.75±2.15 11.35±2.82 11.25±2.00 11.50±2.74 11.60±3.02 |
Compare with matched group
*Expression P＜0.05
*Expression P＜0.01
* *P＜0.001
The result shows: woman's inflammation oral liquid that disappears can significantly suppress by the rat paw edema due to the carrageenin.
Four, to the bullate influence of rat granuloma
Get 45 of rats (female), etherization is imbedded at the aseptic cotton balls of 20mg under the axillary fossa of rat both sides skin suture under the aseptic condition.Postoperative divides 5 groups at random, administration on the same day, and dosage sees Table 4.Administration every day 1 time, continuous 8 days, after the last administration 1 hour, draw neck to put to death rat, weigh.Take out the oven dry of cotton balls granulation tissue, 60 ℃, 8 hours, deducting the raw cotton ball weight with the weight of cotton balls granulation tissue, to be granulation tissue heavy.The results are shown in Table 4.
Table 4 woman inflammation disappears oral liquid to the bullate influence of rat granuloma
| Group (g/kg) | Number of animals (only) | Granulation heavy (mg) | P |
| Contrast FUYANKANG 1.0 woman's inflammation oral liquid 10.0 5.0 2.5 that disappears | 9 9 9 9 9 | 207.00±25.76 169.56±38.63 158.22±30.91 170.33±18.33 187.00±25.62 | ＜0.05 ＜0.01 ＜0.01 ＞0.05 |
The result shows: woman's inflammation oral liquid that disappears can reduce the granulation tissue hyperplasia effect that cotton balls causes.
Five, Dichlorodiphenyl Acetate causes the influence of mouse writhing reaction
Get 50 of male and female mices, divide 5 groups at random, press the gastric infusion of dosage shown in the table 5, once a day, continuous 7 days, after the last administration 1 hour, each mice is the glacial acetic acid 10ml/kg of lumbar injection 0.6% respectively, observed the writhing response number of times of mice in 15 minutes.The results are shown in Table 5.
The table 5 woman inflammation oral liquid Dichlorodiphenyl Acetate that disappears causes the influence of mouse writhing reaction
| Group (g/kg) | Number of animals (only) | Turn round body number of times/15 minute | P |
| Contrast FUYANKANG 1.0 woman's inflammation oral liquid 10.0 5.0 2.5 that disappears | 10 10 10 10 10 | 17.6±6.02 12.2±4.13 9.2±4.13 9.8±7.23 10.6±4.59 | ＜0.05 ＜0.01 ＜0.05 ＞0.05 |
The result shows: woman's inflammation oral liquid that disappears can reduce the mouse writhing reaction times that acetic acid causes.
Six, the woman's inflammation influence of oral liquid that disappear to mice reticuloendothelial system phagocytic function
Get 50 of female mices, divide 5 groups at random, press the gastric infusion of dosage shown in the table 6, every day 1 time, successive administration 7 days, after the last administration 1 hour, each Mus is intravenous injection prepared Chinese ink (one gets pavilion dilution in 1: 4) 10ml/kg respectively, respectively at after the intravenous injection 2 and 15 minutes,, place 0.1%Na by eyeball venous blood collection 0.05ml
2CO
3Among the solution 5ml, after 2 hours in 550nm place colorimetric.The result represents (phagocytic index=logT with phagocytic index
2-logT
15/ 13), the results are shown in Table 6.
The influence of oral liquid that disappear of table 6 woman inflammation to mice reticuloendothelial system phagocytic function
| Group (g/kg) | Number of animals (only) | Phagocytic index | P |
| Contrast FUYANKANG 1.0 woman's inflammation oral liquid 10.0 5.0 2.5 that disappears | 10 10 10 10 10 | 0.0152±0.0064 0.0181±0.0034 0.0222±0.0052 0.0229±0.0092 0.0207±0.0053 | ＜0.05 ＜0.05 ＜0.05 ＞0.05 |
The result shows; Woman's inflammation oral liquid that disappears can increase the phagocytic index of mice to prepared Chinese ink.
Seven, the woman's inflammation influence of oral liquid that disappear to the hemorheology of rat index
Get 40 of rats, divide 5 groups at random, every day, gastric infusion was 1 time, and continuous 28 days, dosage saw Table 7, after the last administration 1 hour, with 0.8% pentobarbital sodium anesthesia 5ml/kg, from abdominal aortic blood (heparin sodium is anti-peaceful), measured whole blood viscosity and plasma viscosity.The results are shown in Table 7.
The influence of oral liquid that disappear of table 7 woman inflammation to rat serum rheology index
| Group (g/kg) | Number of animals (only) | Plasma viscosity (ratio) | Whole blood viscosity (ratio) l/s under different shear rates (l/s) | ||||
| 20 | 30 | 40 | 60 | 80 | |||
| Contrast FUYANKANG 1.0 woman's inflammation disappear 10.0 5.0 2.5 | 8 8 8 8 8 | 1.96±0.26 1.74±0.08 * 1.66±0.10 ** 1.75±0.05 * 1.82±0.20 | 17.68±3.71 12.40±3.26 ** 13.01±1.53 *** 13.01±4.29 * 14.39±4.56 | 15.22±3.35 10.88±2.79 * 10.42±1.18 ** 11.03±3.17 * 12.05±2.86 | 12.48±2.38 9.96±2.93 9.42±1.07 ** 9.58±2.56 * 10.30±2.27 | 10.83±1.91 8.86±2.36 8.56±1.03 ** 8.63±2.12 * 9.21±1.85 | 9.65±1.61 8.14±2.18 7.87±1.01 * 7.79±1.91 8.631.51 |
Compare with matched group
*Expression P＜0.05
*Expression P＜0.01
* *P＜0.001
The result shows: woman's inflammation oral liquid that disappears can reduce whole blood viscosity and the plasma viscosity of rat, and is remarkable with the matched group comparing difference.
Eight, woman's inflammation oral liquid studies on acute toxicity that disappears
Get 20 of mices, water is can't help in fasting 12 hours.Each stomach 0.3ml/10g body weight of irritating is irritated stomach twice in 24 hours, TBW 0.3 * 2 * 2=1.2ml/20g, and total crude drug amount is 1.2 * 7.14 ÷, 20 * 1000=428.4g/kg body weight.Observed 7 after the administration, animal diet followed is normal, weight increase, and the hair color light, activity is not seen other unusual performance freely, does not have dead the generation.
Nine, disappear oral liquid long term toxicity research of woman's inflammation
Give rat oral gavage woman inflammation disappear oral liquid 50g/kg and 10g/kg, every day 1 time, continuous 8 weeks, through general activity behavior observation and hemogram, urine and hepatic and renal function, the overt toxicity reaction is not seen in the histopathology check, the long-term prescription amount is 80 and 16 times of clinical application amount, in conjunction with The acute toxicity tests, illustrate that woman's inflammation oral liquid toxicity that disappears is less, obey safety for a long time.The results are shown in Table 8,9,10.
The influence of oral liquid that disappear of table 8 woman inflammation to rat body weight
| Group (g/kg) | Number of animals (only) | Body weight before the administration | Different time after the administration (week) body weight (g) | |||
| 2 | 4 | 6 | 8 | |||
| ♂ contrast (distilled water) woman inflammation (50) (10) ♀ contrast (distilled water) woman inflammation (50) (10) that disappear that disappear | 10 10 10 10 10 10 | 100.9±12.97 99.1±14.76 100.5±18.43 99.4±21.73 99.5±20.51 100.1±19.05 | 207.2±27.82 206.2±22.91 209.3±23.85 184.7±19.71 185.0±14.56 189.4±15.79 | 278.4±47.53 286.0±25.57 290.1±26.07 228.1±19.15 231.2±23.67 236.1±16.83 | 320.9±47.45 326.6±20.54 318.3±27.95 258.4±20.93 260.8±18.99 257.4±19.96 | 349.6±51.69 355.7±22.37 346.6±30.45 281.422.79 284.1±20.69 280.4±21.74 |
The exponential influence of table 9 pair Rats Organs and Tissues
| Group (g/kg) | Number of animals (only) | Each organ index (g/100g) after 8 weeks of administration | |||||
| The heart | Liver | Spleen | Lung | Kidney | The Utero-ovary | ||
| Contrast (distilled water) woman inflammation (50) (10) that disappear | 10 10 10 | 0.39±0.03 0.41±0.04 0.41±0.03 | 3.27±0.26 3.09±0.23 3.12±0.24 | 0.44±0.22 0.48±0.16 0.52±0.22 | 0.77±0.16 0.78±0.09 0.83±0.14 | 0.75±0.03 0.76±0.04 0.79±0.04 | 0.30±0.07 0.36±0.08 0.35±0.08 |
The influence of oral liquid that disappear of table 10 woman inflammation to rat blood
| Group (g/kg) | Number of animals (only) | RBC ×10 12/l | Hb g/l | WBC ×10 9/l | Pit ×10 9/l | Leaflet % | Lymph % | Clotting time (second) |
| Contrast (distilled water) woman inflammation (50) (10) that disappear | 10 10 10 | 6.67±0.27 6.57±0.34 6.67±0.38 | 117.6±12.86 121.5±13.02 116.6±8.26 | 7.91±1.99 7.85±3.62 8.56±2.89 | 439.±82.19 462.0±63.99 455.0±53.62 | 21.1±1.98 20.9±3.53 20.7±3.23 | 78.9±1.98 79.1±3.53 79.3±3.23 | 139.5±31.00 168.0±40.48 174.0±30.57 |
Come further to set forth the preparation method of medicine of the present invention by the following examples.
The preparation of embodiment 1 medicinal granule of the present invention
A) take by weighing each crude drug by following weight ratio, Radix Angelicae Sinensis 170g, Radix Salviae Miltiorrhizae 170g, Radix Paeoniae Rubra 95g, Rhizoma Corydalis 95g, rhizoma sparganic 95g, Rhizoma Curcumae 95g, Radix Sophorae Flavescentis 95g, Cortex Phellodendri 95g, Rhizoma Smilacis Glabrae 95g, Rhizoma Cyperi 55g are standby;
B) above-mentioned ten flavor crude drug are put in the extraction pot that has volatile oil extractor, decocted with water three times, add 9 times of amounts for the first time, decocted 4 hours, and added 7 times of amounts for the second time, decocted 3 hours, add 4 times of amounts for the third time, decocted 3 hours, with carry volatile oil in addition device preserve, collecting decoction filters, and it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adding ethanol makes and contains alcohol amount and reach 50%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to there not being the alcohol flavor;
C) above-mentioned medicinal liquid is concentrated into the clear paste that relative density is 1.30-1.35, drying gets dry extract.
D) above-mentioned dry extract is broken into powder, with extract volatile oil with a little dissolve with ethanol, sparge in the powder, an amount of with sucrose and dextrin, mixing, with 50% alcohol granulation, dry, granulate, packing, sealing, promptly.
The oral liquid preparation of embodiment 2 medicines of the present invention
A) take by weighing each crude drug by following weight ratio, Radix Angelicae Sinensis 190g, Radix Salviae Miltiorrhizae 190g, Radix Paeoniae Rubra 115g, Rhizoma Corydalis 115g, rhizoma sparganic 115g, Rhizoma Curcumae 115g, Radix Sophorae Flavescentis 115g, Cortex Phellodendri 115g, Rhizoma Smilacis Glabrae 115g, Rhizoma Cyperi 75g are standby;
B) above-mentioned ten flavor crude drug are put in the extraction pot that has volatile oil extractor, decocted with water three times, add 10 times of amounts for the first time, decocted 4 hours, and added 8 times of amounts for the second time, decocted 3 hours, add 6 times of amounts for the third time, decocted 3 hours, with carry volatile oil in addition device preserve, collecting decoction filters, and it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adding ethanol makes and contains alcohol amount and reach 50%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to there not being the alcohol flavor;-4 ℃ freezing 12 hours, treat under its room temperature slowly dissolving after, filter, filtrate adds refined honey 400g, steviosin 15g, sodium benzoate 2.5g;
C) volatile oil of carrying is added with medicinal dissolve with ethanol, adding distil water is adjusted total amount to 1000ml, shakes up, filter, and fill, sterilization, promptly.
The preparation of the capsule of embodiment 3 medicines of the present invention
A) take by weighing each crude drug by following weight ratio, Radix Angelicae Sinensis 210g, Radix Salviae Miltiorrhizae 210g, Radix Paeoniae Rubra 135g, Rhizoma Corydalis 135g, rhizoma sparganic 135g, Rhizoma Curcumae 135g, Radix Sophorae Flavescentis 135g, Cortex Phellodendri 135g, Rhizoma Smilacis Glabrae 135g, Rhizoma Cyperi 95g are standby;
B) above-mentioned ten flavor crude drug are put in the extraction pot that has volatile oil extractor, decocted with water three times, add 14 times of amounts for the first time, decocted 4 hours, and added 10 times of amounts for the second time, decocted 3 hours, add 7 times of amounts for the third time, decocted 3 hours, with carry volatile oil in addition device preserve, collecting decoction filters, and it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adding ethanol makes and contains alcohol amount and reach 50%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to there not being the alcohol flavor;
C) above-mentioned medicinal liquid is concentrated into the clear paste that relative density is 1.30-1.35, drying gets dry extract.
D) above-mentioned dry extract is broken into powder, with extract volatile oil with a little dissolve with ethanol, sparge in the powder, divide in the snap fit capsule of packing into, promptly.
Claims (5)
1, a kind of medicine for the treatment of chronic pelvic inflammatory disease is characterized in that it is to be made by following bulk drugs:
Radix Angelicae Sinensis 170-210 part Radix Salviae Miltiorrhizae 170-210 part Radix Paeoniae Rubra 95-135 part Rhizoma Corydalis 95-135 part
Rhizoma sparganic 95-135 part Rhizoma Curcumae 95-135 part Radix Sophorae Flavescentis 95-135 part Cortex Phellodendri 95-135 part
Rhizoma Smilacis Glabrae 95-135 part Rhizoma Cyperi 55-95 part.
2, a kind of medicine for the treatment of chronic prostatitis according to claim 1 is characterized in that wherein the consumption of each crude drug is:
115 parts of 115 parts of Rhizoma Corydalis of 190 parts of Radix Paeoniae Rubra of 190 parts of Radix Salviae Miltiorrhizaes of Radix Angelicae Sinensis
115 parts of 115 portions of Cortex Phellodendris of 115 parts of Radix Sophorae Flavescentiss of 115 parts of Rhizoma Curcumae of rhizoma sparganic
75 parts of 115 portions of Rhizoma Cyperis of Rhizoma Smilacis Glabrae.
3, the preparation method of claim 1 or 2 described medicines, it comprises the following steps:
A) take by weighing each crude drug, standby;
B) above-mentioned ten flavor crude drug are put in the extraction pot that has volatile oil extractor, decocted with water three times, add 14-9 for the first time and doubly measure, decocted 4 hours, and added 10-7 for the second time and doubly measure, decocted 3 hours, add 7-4 for the third time and doubly measure, decocted 3 hours, with carry volatile oil in addition device preserve, collecting decoction filters, and it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adding ethanol makes and contains alcohol amount and reach 50%, left standstill 24 hours, and filtered, filtrate recycling ethanol is to there not being the alcohol flavor;
C) above-mentioned medicinal liquid is concentrated into the clear paste that relative density is 1.30-1.35, drying gets dry extract;
D) above-mentioned dry extract is broken into powder, with extract volatile oil with a little dissolve with ethanol, sparge in the powder, just be prepared into the active component of invention medicine.
4, the preparation method of medicine according to claim 3, it is characterized in that: step b) is put above-mentioned ten flavor crude drug in the extraction pot that has volatile oil extractor, decoct with water three times, add for the first time 10 times of amounts, decocted 4 hours, and added 8 times of amounts for the second time, decocted 3 hours, add 6 times of amounts for the third time, decocted 3 hours, with carry volatile oil in addition device preserve collecting decoction, filter, it is 1.10-1.15 up to relative density that filtrate concentrates 20 ℃, adds ethanol and makes and contain the alcohol amount and reach 50%, leaves standstill 24 hours, filter, filtrate recycling ethanol is to there not being the alcohol flavor.
5, according to the preparation method of claim 3,4 described medicines, wherein the component that step b) is made-4 ℃ freezing 12 hours, treat under its room temperature slowly dissolving after, filter, filtrate adds 400 parts of refined honeys, 15 parts of steviosin, 2.5 parts of sodium benzoate; The volatile oil of carrying is added with medicinal dissolve with ethanol, and adding distil water is adjusted total amount to 1000ml, shakes up, filter, and fill, sterilization promptly gets oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410010750 CN1256120C (en) | 2004-03-26 | 2004-03-26 | Medicine for treating chronic pelvic inflammation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410010750 CN1256120C (en) | 2004-03-26 | 2004-03-26 | Medicine for treating chronic pelvic inflammation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562113A CN1562113A (en) | 2005-01-12 |
| CN1256120C true CN1256120C (en) | 2006-05-17 |
Family
ID=34477882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410010750 Expired - Fee Related CN1256120C (en) | 2004-03-26 | 2004-03-26 | Medicine for treating chronic pelvic inflammation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256120C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100460003C (en) * | 2005-03-17 | 2009-02-11 | 桂林三金药业股份有限公司 | A kind of pharmaceutical composition and its preparation method and quality control method |
| CN1686503B (en) * | 2005-04-22 | 2010-11-10 | 复旦大学 | External use medicinal preparation for treating pelvic infection |
| CN101926961B (en) * | 2010-08-20 | 2011-11-16 | 刘锦 | Oral Chinese medicinal composition for treating pelvic inflammatory disease |
| CN102847123B (en) * | 2012-09-26 | 2013-12-11 | 张永红 | Drug for treating chronic pelvic inflammatory disease and preparation method of medicine |
| CN104547964A (en) * | 2015-02-13 | 2015-04-29 | 范江诺 | Traditional Chinese medicine composition and preparation for treating chronic pelvic inflammatory disease |
| CN106177845A (en) * | 2016-08-10 | 2016-12-07 | 张成莲 | Palace disease patch |
| CN109876104A (en) * | 2019-04-25 | 2019-06-14 | 湖南省妇幼保健院 | A kind of Chinese medicine composition and Chinese materia medica preparation |
| CN111714568B (en) * | 2019-10-24 | 2021-12-24 | 贵州益佰女子大药厂有限责任公司 | Preparation method of Fuyanxiao preparation |
-
2004
- 2004-03-26 CN CN 200410010750 patent/CN1256120C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1562113A (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | A kind of traditional Chinese medicine composition for treating arthritis or gout and preparation method thereof | |
| CN1256120C (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN103933487A (en) | Compound traditional Chinese medicament for treating depression | |
| CN101780227A (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN101703684A (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN102895387B (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
| CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
| CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN100528214C (en) | Capsule for treating epilepsia and its preparing method | |
| CN104095940B (en) | A kind of Chinese medicine composition for the treatment of gout | |
| CN1836693A (en) | Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN101474315B (en) | A kind of effective component group of zushima and its preparation method and application | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN1268362A (en) | Compound Chinese herb medicine for curing fibrosis of liver and hepatocirrhosis and its preparation method | |
| CN105920130A (en) | Preparation method and externally used ointment of traditional Chinese medicine for treating talalgia | |
| CN1895367A (en) | Chinese-medicinal preparation for treating coronary heart disease and angina cordis and its preparation | |
| CN102631497B (en) | a health care composition | |
| CN102284036A (en) | Gujinwan capsule and preparation method thereof | |
| CN1931213A (en) | Tuniclike psammosilene root extract and its prep. medicine composition and use | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN116270949A (en) | Traditional Chinese medicine composition for reducing hyperuricemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jilin yinnuoke Pharmaceutical Co.,Ltd. Assignor: Liu Xiaofeng Contract fulfillment period: 2009.9.2 to 2019.9.1 Contract record no.: 2009220000078 Denomination of invention: Medicine for treating chronic pelvic inflammation and its preparing process Granted publication date: 20060517 License type: Exclusive license Record date: 20091027 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.2 TO 2019.9.1; CHANGE OF CONTRACT Name of requester: JILIN PROVINCE YINNUOKE PHARMACY CO., LTD. Effective date: 20091027 |
|
| EM01 | Change of recordation of patent licensing contract |
Change date: 20160413 Contract record no.: 2009220000078 Assignee after: Zhenlai Bao Kang Pharmaceutical Co. Assignee before: Jilin yinnuoke Pharmaceutical Co.,Ltd. |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160601 Address after: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee after: Zhenlai Bao Kang Pharmaceutical Co. Address before: 130031 No. 23, conference Avenue, Changchun economic and Technological Development Zone, Jilin, China Patentee before: Liu Xiaofeng |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee after: Jilin yinnuoke pharmaceutical Limited by Share Ltd. Address before: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee before: Zhenlai Bao Kang Pharmaceutical Co. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Jilin, Baicheng Patentee after: Jilin yinnuoke Pharmaceutical Co.,Ltd. Address before: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee before: Jilin yinnuoke pharmaceutical Limited by Share Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060517 |